Post by
geodcan on Jan 04, 2022 1:49pm
91% uptick on otc on latest nr
for Ed's highly endorsed product hitting shelves in Europe.
Consumers everywhere want to give themselves an edge or boost and are searching out skus that will give them a sense that they are doing something good for themselves.
For as long as cannabinoids have been around, there is a lot to be done, proving up the effects of them and enlightening the buying public as to what they will do for you.
Of course Pharma use is demanding 7 years of testing to actually make the claims that manufacturers are hinting at and consumers are figuring it out for themselves from word of mouth and info from sales assistants in cannabinoid shops.
I'm not sure what Neuenergy has in it but we are leaning towards cannabinoids and terpene products and the huge potential that they bring that has also been stifled by US law and policy makers not allowing access to the labs that want to explore and prove what a lot of pot and hemp consumers already know, that this type of products show great potential for more than just seizures.
Not too many US investors today but I know there is a whole segment looking for multi-baggers and NU/ NRXCF is one of my favourites for their ability to drop a nr and spike up the sp.
This is not a sure thing but NU has been around for 10 years and closer to a breakout now than they have been in the past.
glta and dyodd